Welcome to our dedicated page for Inozyme Pharma news (Ticker: $INZY), a resource for investors and traders seeking the latest updates and insights on Inozyme Pharma stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Inozyme Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Inozyme Pharma's position in the market.
Inozyme Pharma (Nasdaq: INZY), a clinical-stage biopharmaceutical company specializing in rare diseases, announced that its CEO and Chairman, Doug Treco, Ph.D., will present at the Jefferies Global Healthcare Conference. The presentation is scheduled for Thursday, June 6, 2024, from 12:30 to 12:55 pm ET. A live webcast will be available on the Investor Relations section of Inozyme's website, with a replay accessible for a time.
Inozyme Pharma (Nasdaq: INZY) announced that it will present topline data from its Phase 1/2 clinical trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency at two upcoming medical conferences. The presentations will occur at the European Calcified Tissue Society Congress (ECTS) 2024 in Marseille, France, from May 25-28, and at the Endocrine Society's Annual Meeting (ENDO) 2024 in Boston, Massachusetts, from June 1-4. Key topics include the impact of INZ-701 on bone and mineral metabolism biomarkers and clinical outcomes in adults with ENPP1 Deficiency, as well as the safety and exploratory efficacy of INZ-701 in adults with ABCC6 Deficiency manifesting as pseudoxanthoma elasticum (PXE).
Inozyme Pharma, Inc. (Nasdaq: INZY) will participate in the Bank of America Securities 2024 Health Care Conference with CEO Doug Treco. The company focuses on developing therapeutics for rare diseases related to mineralization and intimal proliferation.
Inozyme Pharma, Inc. (Nasdaq: INZY) reported positive interim data from Phase 1 trials of INZ-701 in end-stage kidney disease and ENPP1 Deficiency. Cash on hand expected to fund operations into Q4 2025. The company aims to address unmet needs in ABCC6 Deficiency and calciphylaxis. Financially, cash, cash equivalents, and short-term investments were $166.2 million, with R&D expenses at $19.1 million and net loss of $23.3 million for Q1 2024.
Inozyme Pharma, Inc. (Nasdaq: INZY) granted stock options to a new employee under Nasdaq Listing Rule 5635(c)(4). The options allow the purchase of up to 20,000 shares at $4.61 per share, vesting over four years.